Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 34Terminated 18Recruiting 14Active not recruiting 6Unknown 5Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 35Breast Neoplasms 30Prostatic Neoplasms 21Leukemia, Myeloid, Acute 20Colorectal Neoplasms 20Pancreatic Neoplasms 17Melanoma 17Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 15Lung Neoplasms 13Brain Neoplasms 13Glioma 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Carcinoma, Hepatocellular 11Ovarian Neoplasms 10Multiple Myeloma 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Carcinoma, Renal Cell 8Leukemia 7Sarcoma 6Rectal Neoplasms 6Hematologic Neoplasms 6Esophageal Neoplasms 6Uterine Cervical Neoplasms 5Recurrence 5

Interventions

venetoclax 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × Hereditary Sensory and Autonomic Neuropathies × Clear all
NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Curis, Inc.

Phase 1/2 Suspended
366 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡